CRBP · Corbus Pharmaceuticals Holdings, Inc.

Track CRBP — free

$5.80 -0.33 (-5.38%)

Russell 2000 member Rebalance outlook locked

Market Cap

$130.36M

19.34M

Volume · Oct 5 793K Avg daily vol (3M) 716.64K

Up next

Next earnings call

Jan 3, 2027 Est · unconfirmed · in 13 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q4 2020 earnings call transcript

call held Mar 15, 2021

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$101.90M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+58.6%

Year over year · more shares

Price change (1Y)

-52.9%

Trailing year

Short interest

14.3%

Latest settlement · 1.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −32%

below

Price vs 50-day avg −33%

below

RSI (14) 26

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −47%

trailing

6-month return −40%

trailing

YTD return −25%

this year

Relative strength −52%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $9 › 200d $9 — 50d above 200d

Institutional flow Accumulating

2 of 107 funds reported for Sep 30 · net +76.0K sh shares · +1 new

Insider flow Accumulating

Net +$25.0K over 90 days · 0% sells

Short interest Rising

14.27% of float · ▲ +22.9% MoM · 1.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

107 holders — mid 3-yr range

Squeeze score 65

elevated · 0–100

Fundamentals

Weak

Revenue growth +98%

Y/Y

EPS growth −60%

Y/Y

Free cash flow $-64.5M

Balance sheet $2.2M

net debt

Quant / Vol

risk profile

Very High

Volatility 82%

annualized · 1-yr

Max drawdown −68%

past year

ATR 9.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−32% Bearish

Price vs 50-day avg

−33% Bearish

RSI (14)

26 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $9 › 200d $9 — 50d above 200d

Institutional flow Accumulating

2 of 107 funds reported for Sep 30 · net +76.0K sh shares · +1 new

Insider flow Accumulating

Net +$25.0K over 90 days · 0% sells

Short interest Rising

14.27% of float · ▲ +22.9% MoM · 1.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

107 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $6 Now $6 · 0% Range high $19

vs 200-day avg -32% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRBP Corbus Pharmaceuticals Holdings, Inc. this stock	$130.36M	-24.7%	+97.6%	—	14.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

108

% held: 80.5%
Reported: 2 of 107
Top holder: Cormorant Asset Managemen…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

2.8M

Days to cover: 1.5d
Change: +513.3K sh

View

Short Volume

Short vol %

44%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

421

Value: $3.5K
As of: Sep 11, 2026

View

Off-Exchange

Off-exchange %

45.9%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$25.0K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-78.5M
EPS diluted: $-5.90

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 14, 2026
This year: 19

View

Proposed Sales

Value

$121.0K

Shares: 12.0K
Filed: Aug 7, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 14, 2026

View

Performance

	5D	20D	120D	MTD	YTD
CRBP	-14.2%	-46.5%	-39.8%	-10.1%	-24.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-13.9%	-46.1%	-52.0%	-11.0%	-37.6%

Key facts CIK 1595097 CUSIP 21833P301 13F (30d) 4 filings 4 filers Visit website Investor relations

CRBP · Corbus Pharmaceuticals Holdings, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance